Bevasiranib reaches the retina
Bevasiranib, a small interfering RNA (siRNA) compound targeting vascular endothelial growth factor-A (VEGF-A), is distributed throughout the eye, including the retina, according to a study published on 28 May 2008 in Molecular Vision.
Bevasiranib, a small interfering RNA (siRNA) compound targeting vascular endothelial growth factor-A (VEGF-A), is distributed throughout the eye, including the retina, according to a study published on 28 May 2008 in Molecular Vision.
Nadine S. Dejneka, of OPKO Ophthalmics, US, and colleagues conducted a tissue distribution and pharmacokinetic study to determine how a single intravitreal injection (either 0.5 or 2.0 mg/eye) of bevasiranib, developed by OPKO Health Inc., US, was distributed in rabbit eyes (64 eyes of 32 rabbits).
Twenty-four hours post-injection, bevasiranib was detected in the vitreous, iris, retina, retinal pigment epithelium (RPE), and sclera (+choroid). After the initial 24 hours, levels of bevasiranib in the vitreous began to drop; maximum saturation in non-vitreous ocular tissues was reached up to 72 hours post-injection.
The researchers believe that these results of distribution to the retina provide significant evidence for the use of bevasiranib against wet age-related macular degeneration (AMD), as is currently being evaluated in the international Phase III COBALT study.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
